

F. No. 31026/06/2016-PI.I(Pt)  
Government of India  
Ministry of Chemicals & Fertilizers  
Department of Pharmaceuticals  
(Pricing Division)

3<sup>rd</sup> Floor, B-Wing, Janpath Bhawan,  
Jaapath, New Delhi dated 04.05.2016

OFFICE MEMORANDUM

**Sub:- Availability of tablets glimestar PM1 & PM2 – regarding.**

The undersigned is directed to say that this Department has received two email messages from Shri Domendra Sahu dated 25.04.2016 and Shri Mega Nathan dated 18.04.2016 (copy enclosed) on the above mentioned subject and to say that the matter was referred to National Pharmaceutical Pricing Authority (NPPA). As per report received from NPPA, it was inferred that:-

- The references regarding shortage of medicines relates to medicines having similar combination as contained in the medicines Glimestar PM1 & PM2 (Anti-diabetics medicines).
- These medicines are basically the combinations of Glimepiride, Pioglitazone and Metformin having different strengths. The combination of medicines congaing Glimepiride, Pioglitazone and Metformin is banned by Ministry of Health and Family Welfare vide Circular Number DCGI/MISC/2016 (32) dated 12.03.2016 (Gazette Notifications Number 608 dated 10.03.2016).
- As per this notification / circular, medicines having the combinations cannot be manufactured, sold or distributed in the country.

2. Since medicines having the combination as mentioned above are banned, MoH&FW is requested to kindly issue an advisory to doctors for prescribing alternative medicines which have not been banned.

(M.K. Bhardwaj)  
Deputy Secretary to the Govt. of India  
Tel: 23752664

Department of Health & Family Welfare,  
(Kind attention:-Shri K. L. Sharma, Joint Secretary)  
Room No. 151-A, Nirman Bhawan,  
New Delhi.

Ward  
S/S/16  
que, with

DD(M&R)